Absence of the RNF213 p.R4810K variant may indicate a severe form of pediatric moyamoya disease in Japanese patients

Shoko Hara MD, PhD1, Maki Mukawa MD, PhD1, Hiroyuki Akagawa MD, PhD2,3, Thiparpa Thamamongood MD1, Motoki Inaji MD, PhD1, Yoji Tanaka MD, PhD1, Taketoshi Maehara MD, PhD1, Hidetoshi Kasuya MD, PhD2,3, and Tadashi Nariai MD, PhD1
View More View Less
  • 1 Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo;
  • | 2 Department of Neurosurgery, Tokyo Women’s Medical University Institute for Integrated Medical Sciences, Tokyo; and
  • | 3 Department of Neurosurgery, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

OBJECTIVE

The authors’ objective was to investigate the influence of the RNF213 p.R4810K variant on the clinical presentation and outcomes of Japanese pediatric patients with moyamoya disease.

METHODS

A total of 129 Japanese patients with pediatric-onset moyamoya disease (onset age ≤ 15 years) who visited the authors’ department from 2012 to 2020 participated in this study. After RNF213 p.R4810K genotyping of each patient was performed, the relationship between genotype and clinical presentation or outcomes, including onset age, initial presentation, surgical outcomes, and subsequent cerebrovascular events, was evaluated. Patients without the p.R4810K variant were tested for RNF213 variants other than p.R4810K. The authors especially focused on the results of patients who presented with moyamoya disease at younger than 1 year of age (infantile onset).

RESULTS

Compared with the patients with heterozygous variants, patients without the p.R4810K variant were younger at onset (7.1 ± 3.7 vs 4.4 ± 0.9 years), and all 4 patients with infantile onset lacked the p.R4810K variant. A greater proportion of patients without the p.R4810K variant presented with infarction than patients with the heterozygous variant (24.0% vs 7.6%) and a decreased proportion presented with transient ischemic attack (36.0% vs 71.7%). No significant correlation was observed between p.R4810K genotype and clinical outcomes, including surgical outcomes and subsequent cerebrovascular events; however, a decreased proportion of patients without the p.R4810K variant had good surgical outcomes compared with that of patients with the heterozygous variant (76.5% vs 92.2%). Among the 25 patients without the p.R4810K variant, 8 rare variants other than p.R4810K were identified. Three of 4 patients with infantile onset had RNF213 variants other than p.R4810K, which had a more severe functional effect on this gene than p.R4810K.

CONCLUSIONS

Absence of the RNF213 p.R4810K variant may be a novel biomarker for identification of a severe form of pediatric moyamoya disease.

ABBREVIATIONS

CADD = Combined Annotation Dependent Depletion; EDAS = encephalo-duro-arterio-synangiosis; EDPS = encephalo-duro-pericranio-synangiosis; mRS = modified Rankin Scale; PCA = posterior cerebral artery.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Tominaga T, Suzuki N, Miyamoto S, Koizumi A, Kuroda S, Takahashi JC, et al. Recommendations for the Management of Moyamoya Disease: A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease). [2nd Edition]. Surg Cereb Stroke. 2018;46(1):124.

    • Search Google Scholar
    • Export Citation
  • 2

    Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6(7):e22542.

    • Search Google Scholar
    • Export Citation
  • 3

    Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56(1):3440.

    • Search Google Scholar
    • Export Citation
  • 4

    Morimoto T, Mineharu Y, Kobayashi H, Harada KH, Funaki T, Takagi Y, et al. Significant association of the RNF213 p.R4810K polymorphism with quasi-moyamoya disease. J Stroke Cerebrovasc Dis. 2016;25(11):26322636.

    • Search Google Scholar
    • Export Citation
  • 5

    Nomura S, Akagawa H, Yamaguchi K, Ishikawa T, Kawashima A, Kasuya H, et al. Rare and low-frequency variants in RNF213 confer susceptibility to moyamoya syndrome associated with hyperthyroidism. World Neurosurg. 2019;127:e460e466.

    • Search Google Scholar
    • Export Citation
  • 6

    Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78(11):803810.

    • Search Google Scholar
    • Export Citation
  • 7

    Zhang Q, Ge P, Ma Y, Zhang D, Wang R, Zhang Y, et al. Clinical features and surgical outcomes of patients with moyamoya disease and the homozygous RNF213 p.R4810K variant. J Child Neurol. 2019;34(13):793800.

    • Search Google Scholar
    • Export Citation
  • 8

    Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, et al. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. J Neurosurg. 2017;126(4):11061113.

    • Search Google Scholar
    • Export Citation
  • 9

    Wang Y, Zhang Z, Wei L, Zhang Q, Zou Z, Yang L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease. Neurology. 2020;94(7):e678e686.

    • Search Google Scholar
    • Export Citation
  • 10

    Kim EH, Yum MS, Ra YS, Park JB, Ahn JS, Kim GH, et al. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. J Neurosurg. 2016;124(5):12211227.

    • Search Google Scholar
    • Export Citation
  • 11

    Mukawa M, Nariai T, Matsushima Y, Tanaka Y, Inaji M, Maehara T, et al. Long-term follow-up of surgically treated juvenile patients with moyamoya disease. J Neurosurg Pediatr. 2012;10(5):451456.

    • Search Google Scholar
    • Export Citation
  • 12

    Mukawa M, Nariai T, Onda H, Yoneyama T, Aihara Y, Hirota K, et al. Exome sequencing identified CCER2 as a novel candidate gene for moyamoya disease. J Stroke Cerebrovasc Dis. 2017;26(1):150161.

    • Search Google Scholar
    • Export Citation
  • 13

    Akagawa H, Mukawa M, Nariai T, Nomura S, Aihara Y, Onda H, et al. Novel and recurrent RNF213 variants in Japanese pediatric patients with moyamoya disease. Hum Genome Var. 2018;5:17060.

    • Search Google Scholar
    • Export Citation
  • 14

    Aoyama J, Nariai T, Mukawa M, Inaji M, Tanaka Y, Maehara T. Case of familial moyamoya disease presenting 10 years after initial negative magnetic resonance screening in childhood. World Neurosurg. 2017;105:1035.e11035.e4.

    • Search Google Scholar
    • Export Citation
  • 15

    Hara S, Shimizu K, Nariai T, Kishino M, Kudo T, Umemoto T, et al. De novo renal artery stenosis developed in initially normal renal arteries during the long-term follow-up of patients with moyamoya disease. J Stroke Cerebrovasc Dis. 2020;29(8):104786.

    • Search Google Scholar
    • Export Citation
  • 16

    Kanamori F, Araki Y, Yokoyama K, Uda K, Nishihori M, Izumi T, et al. Brain compression by encephalo-myo-synangiosis is a risk factor for transient neurological deficits after surgical revascularization in pediatric patients with moyamoya disease. World Neurosurg. 2020;133:e558e566.

    • Search Google Scholar
    • Export Citation
  • 17

    Yamamoto S, Kashiwazaki D, Uchino H, Saito H, Akioka N, Kuwayama N, Kuroda S. Clinical and radiological features of childhood onset adult moyamoya disease: implication for hemorrhagic stroke. Neurol Med Chir (Tokyo). 2020;60(7):360367.

    • Search Google Scholar
    • Export Citation
  • 18

    Mukawa M, Nariai T, Inaji M, Tamada N, Maehara T, Matsushima Y, et al. First autopsy analysis of a neovascularized arterial network induced by indirect bypass surgery for moyamoya disease: case report. J Neurosurg. 2016;124(5):12111214.

    • Search Google Scholar
    • Export Citation
  • 19

    Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T. Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovasc Dis. 2005;20(5):347354.

    • Search Google Scholar
    • Export Citation
  • 20

    Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T. How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst. 2004;20(10):734741.

    • Search Google Scholar
    • Export Citation
  • 21

    Matsushima Y, Inaba Y. Moyamoya disease in children and its surgical treatment. Introduction of a new surgical procedure and its follow-up angiograms. Childs Brain. 1984;11(3):155170.

    • Search Google Scholar
    • Export Citation
  • 22

    Nariai T. Indirect bypass surgery for moyamoya disease. In: Kuroda S, ed. Moyamoya Disease: Current Knowledge and Future Perspectives. Springer Nature;2021:301310.

    • Search Google Scholar
    • Export Citation
  • 23

    Hirai S, Inaji M, Tanaka Y, Hara S, Nariai T, Maehara T. Correlation between clinical presentations and hemodynamic parameters measured by dynamic susceptibility contrast magnetic resonance imaging in adult patients with moyamoya disease. J Stroke Cerebrovasc Dis. 2017;26(12):28142820.

    • Search Google Scholar
    • Export Citation
  • 24

    Hara S, Tanaka Y, Ueda Y, Hayashi S, Inaji M, Ishiwata K, et al. Noninvasive evaluation of CBF and perfusion delay of moyamoya disease using arterial spin-labeling MRI with multiple postlabeling delays: comparison with 15O-gas PET and DSC-MRI. AJNR Am J Neuroradiol. 2017;38(4):696702.

    • Search Google Scholar
    • Export Citation
  • 25

    Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310315.

    • Search Google Scholar
    • Export Citation
  • 26

    Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434443.

    • Search Google Scholar
    • Export Citation
  • 27

    Higasa K, Miyake N, Yoshimura J, Okamura K, Niihori T, Saitsu H, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61(6):547553.

    • Search Google Scholar
    • Export Citation
  • 28

    Ge P, Ye X, Liu X, Deng X, Wang R, Zhang Y, et al. Association between p.R4810K variant and long-term clinical outcome in patients with moyamoya disease. Front Neurol. 2019;10:662.

    • Search Google Scholar
    • Export Citation
  • 29

    Ravindran K, Wellons JC, Dewan MC. Surgical outcomes for pediatric moyamoya: a systematic review and meta-analysis. J Neurosurg Pediatr. 2019;24(6):663672.

    • Search Google Scholar
    • Export Citation
  • 30

    Kimiwada T, Hayashi T, Shirane R, Tominaga T. Posterior cerebral artery stenosis and posterior circulation revascularization surgery in pediatric patients with moyamoya disease. J Neurosurg Pediatr. 2018;21(6):632638.

    • Search Google Scholar
    • Export Citation
  • 31

    Nomura S, Yamaguchi K, Akagawa H, Kawashima A, Moteki Y, Ishikawa T, et al. Genotype-phenotype correlation in long-term cohort of Japanese patients with moyamoya disease. Cerebrovasc Dis. 2019;47(3-4):105111.

    • Search Google Scholar
    • Export Citation
  • 32

    Ge P, Zhang Q, Ye X, Liu X, Deng X, Wang J, et al. Angiographic characteristics in moyamoya disease with the p.R4810K variant: a propensity score-matched analysis. Eur J Neurol. 2020;27(5):856863.

    • Search Google Scholar
    • Export Citation
  • 33

    Moteki Y, Onda H, Kasuya H, Yoneyama T, Okada Y, Hirota K, et al. Systematic validation of RNF213 coding variants in Japanese patients with moyamoya disease. J Am Heart Assoc. 2015;4(5):e001862.

    • Search Google Scholar
    • Export Citation
  • 34

    Wang X, Wang Y, Nie F, Li Q, Zhang K, Liu M, et al. Association of genetic variants with moyamoya disease in 13 000 individuals: a meta-analysis. Stroke. 2020;51(6):16471655.

    • Search Google Scholar
    • Export Citation
  • 35

    Kazumata K, Ito M, Uchino H, Nishihara H, Houkin K. Proposal for a prospective registry for moyamoya disease in Japan. Neurol Med Chir (Tokyo). 2017;57(2):6672.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 552 552 126
Full Text Views 64 64 10
PDF Downloads 82 82 15
EPUB Downloads 0 0 0